Use of P2Y12 inhibitors among Medicaid beneficiaries between 2008 and 2018

被引：0
|
作者：
Fatani, Nayyra [1 ,2 ,3 ]
Fanikos, Christopher [4 ]
Ting, Clara [1 ]
Buckley, Leo F. [1 ]
Fanikos, John [1 ]
机构：
[1] Brigham & Womens Hosp, Dept Pharm Serv, 45 Francis St, Boston, MA 02115 USA
[2] MCPHS Univ, Dept Pharm Practice, Boston, MA USA
[3] King Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Jeddah, Saudi Arabia
[4] Yale Univ, Sch Publ Hlth, New Haven, CT USA
来源：
JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2019年 / 48卷 / 04期
关键词：
DUAL ANTIPLATELET THERAPY; FOCUSED UPDATE;
D O I：
10.1007/s11239-019-01925-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：539 / 541
页数：3
相关论文
共 50 条
  • [21] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [22] Elderly patients are hyperresponsive to potent P2Y12 inhibitors
    Mutschlechner, D.
    Tscharre, M.
    Wadowski, P.
    Lee, S.
    Pultar, J.
    Weikert, C.
    Panzer, S.
    Gremmel, T.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [23] Republished Education in Heart: New P2Y12 inhibitors
    Storey, Robert F.
    POSTGRADUATE MEDICAL JOURNAL, 2012, 88 (1035) : 49 - 54
  • [24] P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
    Scott, Day Marice
    Norwood, Rhonda M.
    Parra, David
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (01) : 64 - 76
  • [25] P2Y12 inhibitors: do they increase cancer risk?
    Fierro, Joseph J.
    Cave, Brandon
    Khouzam, Rami N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (17)
  • [26] Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries
    Ijaz, Sardar Hassan
    Baron, Suzanne J.
    Shahnawaz, Areeba
    Kulbak, Guy
    Levy, Michael
    Ganatra, Sarju
    Resnic, Frederic
    Dani, Sourbha S.
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (05)
  • [27] Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans
    Singh, Manisha
    Raghavan, Deepa
    Williams, James S.
    Martin, Bradley C.
    Hudson, Teresa J.
    Owen, Richard R.
    Jain, Nishank
    AMERICAN JOURNAL OF NEPHROLOGY, 2018, 47 (02) : 67 - 71
  • [28] Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018
    Kumar, Arun
    Lutsey, Pamela L.
    Peter, Wendy St L.
    Schommer, Jon C.
    Van't Hof, Jeremy R.
    Rajpurohit, Abhijeet
    Farley, Joel F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 1886 - 1897
  • [29] Use of Tirofiban as a bridge to cardiac surgery in patients under treatment with P2Y12 inhibitors
    Jarma, Joaquin J.
    Mando, Florencia
    Ordonez, Santiago
    Etchepare, Alvaro
    Baeck, Ines M.
    Trivi, Marcelo
    Costabel, Juan P.
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2018, 47 (03): : 135 - 139
  • [30] Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists
    Henrich, Andrea
    Claussen, Christian Hove
    Dingemanse, Jasper
    Krause, Andreas
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (07): : 735 - 747
12345